| Ticker: | VPHM | 76 Great Valley Parkway | |
| Exchange: | NASDAQ-National Market | Malvern, Pennsylvania 19355 | |
| Industry: | Manufacturing | (610) 651-0200 |
| Type of Shares: | Common Shares | Filing Date: | 9/20/96 | |
| U.S. Shares: | 2,250,000 | Offer Date: | 11/19/96 | |
| Non-U.S. Shares: | 0 | Filing Range: | $11.00 - $13.00 | |
| Primary Shares: | 2,250,000 | Offer Price: | $7.00 | |
| Secondary Shares: | 0 | Gross Spread: | $0.49 | |
| Offering Amount: | $27,000,000 | Selling: | $0.28 | |
| Expenses: | $551,450 | Reallowance: | $0.10 | |
| Shares Out After: | 8,820,951 |
| Manager | Tier | Phone |
| Cowen & Company | Lead Manager | (212) 495-6000 |
| J.P. Morgan Securities Inc. | Co-manager | (212) 648-9922 |
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 6/30/96 | 6/30/95 | 6/30/96 | ||
| Revenue: | $0.09 | $0.00 | $0.00 | Assets: | $8.96 |
| Net Income: | -$3.85 | -$3.22 | -$1.04 | Liabilities: | $1.59 |
| EPS: | -$0.90 | -$0.52 | Equity: | $7.37 | |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company is a drug manufacturer working to discover and develop pharmaceuticals to treat diseases caused by RNA viruses, including viral meningitis, summer flu, the common cold, influenza, hepatitis C and viral pneumonia. The company has focused its initial drug development and discovery activities on six RNA virus diseases: viral meningitis, "summer flu", the common cold, influenza, hepatitis C and viral pneumonia. Each year, the majority of the world's population is afflicted by at least one of these diseases, for which antiviral therapies are currently either inadequate or unavailable. The company's most advanced compound, pleconaril, previously designated VP 63843, is currently being developed for the treatment of these three diseases. RNA viruses are responsible for the majority of human viral diseases, causing illness ranging from acute and chronic ailments to fatal infections. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used to further develop pleconaril, a drug to treat meningitis, summer flu and the common cold; funds will also go toward research and development, clinical trials and marketing of other drugs and general corporate purposes, which may include capital equipment expenditures. |
©1996 IPO Data Systems, Inc. - All rights reserved.